All In MedTech

Device Trial Radar · NCT01136369

Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Clinical Evaluation of LS-03M/LS-04R for the Detection of Sentinel Lymph Node Metastasis From Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

496

Actual

Start

Feb 2007

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
Sysmex America, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 3, 2010

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H\&E) and IHC staining.

Conditions

  • Breast Neoplasms
  • Breast Diseases

Interventions

  • OSNA Breast Cancer SystemDevice

    For in vitro diagnostic use only. The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm). Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section staining.Time frame: 2 years
  2. The time required to perform the trial method will be measured and evaluated for intra-operative use.Time frame: 2 Years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • John Wayne Cancer Institute

    Santa Monica, California

  • WellStar Health Systems

    Marietta, Georgia

  • Washington University Medical School

    St Louis, Missouri

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.